Integra Lifesciences Holdings
Open
$10.49
Prev. Close
$10.48
High
$10.56
Low
$10.49
Market Snapshot
$785.15M
-1.5
-0.09
$1.61B
Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. The company is headquartered in Princeton, New Jersey and currently employs 4,427 full-time employees. The firm manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.
emptyResult
Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. The company is headquartered in Princeton, New Jersey and currently employs 4,427 full-time employees. The firm manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, plastics and surgical reconstruction products, and others.
Recently from Cashu
Integra Lifesciences Holdings: Leading Innovation in Medical Technology and Regenerative Medicine
Innovative Growth in the Health Sector: Integra Lifesciences Holdings' Strategic Positioning In the current healthcare landscape, companies adept at delivering innovative solutions continue to emerge…
Integra LifeSciences: Focus on Innovation to Enhance Healthcare Solutions and Patient Outcomes
Integra LifeSciences Holdings: The Growing Importance of Innovative Healthcare Solutions Integra LifeSciences Holdings is well-positioned amidst the ongoing advancements in the healthcare sector, part…
Integra Lifesciences Holdings Set for Key Earnings Report Amid Market Volatility
Integra Resources Prepares for Critical Earnings Announcement Amid Market Fluctuations Integra Resources is on the brink of releasing its quarterly earnings report on November 12, 2025, a pivotal mome…
Integra Lifesciences Holdings Set for Key Earnings Report Amid Market Anticipation
Integra Resources Prepares for Key Earnings Announcement Amid Market Anticipation Integra Resources is gearing up for its quarterly earnings report set to be released on November 12, 2025. This announ…